Drug
Utrogestan clinical trials
A product of Progesterone; its studies count on that page too.
- studies test it
- 10
- open now
- 4
- in phase 3
- 3
- first study started
- 2003
Keep track of what changes. Save the Utrogestan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
10 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2013 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 1
- Phase 2
- 1
- Phase 3
- 3
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 9
National University of Malaysia (1) · King's College Hospital NHS Trust (1) · Simone Broer (1) · Shaare Zedek Medical Center (1) · Calla Lily Clinical Care Ltd (1) · UMC Utrecht (1) · Emory University (1) · Insel Gruppe AG, University Hospital Bern (1)
Often tested with
Tested in the same studies.
Nafarelin (2) · Estradiol, estriol drug combination (1) · 17 alpha-Hydroxyprogesterone Caproate (1)
Studies
Open first, then newest update. How each study uses Utrogestan is read from its arms, and is right about nine times in ten.
Testing it · 10
- First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase InsufficiencyRecruitingPhase 1Calla Lily Clinical Care LtdNCT07136922Written as Cyclogest 400 mg
- Progesterone Luteal Support in Unexplained Infertility ManagementNot yet recruitingPhase 3Simone BroerNCT07738068Written as Utrogestan® 200 mg Soft Capsule
- Luteal Phase Support in IUI MOH Treatment Luteal Phase Support in IUI MOH TreatmentRecruitingPhase 4UMC UtrechtNCT05080569Written as Progesterone Vaginal Product
- Comparison of Pregnancy Rates in Modified Natural Frozen Embryo Transfer (FET) Cycle After Luteal Support with GnRH Agonist Versus ProgesteroneNot yet recruitingEarly Phase 1Shaare Zedek Medical CenterNCT06870266Written as Utrogestan®
- Natural Progesterone for the Treatment of Recurrent GlioblastomaTerminatedEarly Phase 1Emory UniversityNCT05091866Written as Therapeutic Progesterone
- Comparison Between Vaginal Pessary and Progestogen in Twin Pregnancy With Short Cervical LengthCompletedPhase 3National University of MalaysiaNCT04342585Written as Micronised vaginal progesterone
- Progesterone and Resting Energy ExpenditureTerminatedPhase 4Insel Gruppe AG, University Hospital BernNCT04140968Written as Utrogestan
- Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High RespondersStatus unknownPhase 4Assaf-Harofeh Medical CenterNCT04797338Written as Utrogestan
- Utrogestan Versus Nifedipine as Tocolysis for Preterm Labor: a Randomised Controlled TrialStatus unknownPhase 2nor zila hassan malekNCT01985594Written as utrogestan
- Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled TrialCompletedPhase 3King's College Hospital NHS TrustNCT00422526Written as Micronised progesterone (Utrogestan)
As the comparator · 3 — what is tested is compared with Utrogestan
- Fasting Bioequivalence Study of 2 Oral Progesterone Soft Capsules 200 mg in 48 Healthy Female SubjectsCompletedPhase 1Joint Stock Company "Farmak"NCT05125640Written as Utrogestan® 200 mg Soft Capsule (Manufacturer by: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)
- Fasting Bioequivalence Study of 2 Progesterone Soft Capsules 200 mg in 66 Healthy Female Subjects Under Vaginal RouteCompletedPhase 1Joint Stock Company "Farmak"NCT05125627Written as Utrogestan® 200 mg Soft Capsule (Manufacturer: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)
- Implantation Enhancement by Elective Cryopreservation of All Viable EmbryosCompletedNot applicableUniversitair Ziekenhuis BrusselNCT02148393Written as Utrogestan®